wow-inequalities/02-data/intermediate/wos_sample/8820960b338ff1d3625840e1e00028e1-neuner-joan-m.-and/info.yaml

115 lines
3.8 KiB
YAML

abstract: 'Purpose Over 50\% of breast cancer patients prescribed a 5-year course
of daily oral adjuvant endocrine therapy (ET) are nonadherent. We
investigated the role of costs and cancer medication delivery mode and
other medication delivery factors on adherence. Methods We conducted a
retrospective cohort study of commercially insured and Medicare
advantage patients with newly diagnosed breast cancer in 2007-2015 who
initiated ET. We examined the association between 12-month ET adherence
(proportion of days covered by fills >= 0.80) and ET copayments, 90-day
prescription refill use, mail order pharmacy use, number of pharmacies,
and synchronization of medications. We used regression models to
estimate nonadherence risk ratios adjusted for demographics (age,
income, race, urbanicity), comorbidities, total medications, primary
cancer treatments, and generic AI availability. Sensitivity analyses
were conducted using alternative specifications for independent
variables. Results Mail order users had higher adherence in both
commercial and Medicare-insured cohorts. Commercially insured patients
who used mail order were more likely to be adherent if they had low
copayments (< \$5) and 90-day prescription refills. For commercially
insured patients who used local pharmacies, use of one pharmacy and
better synchronized refills were also associated with adherence. Among
Medicare patients who used mail order pharmacies, only low copayments
were associated with adherence, while among Medicare patients using
local pharmacies both low copayments and 90-day prescriptions were
associated with ET adherence. Conclusion Out-of-pocket costs, medication
delivery mode, and other pharmacy-related medication delivery factors
are associated with adherence to breast cancer ET. Future work should
investigate whether interventions aimed at streamlining medication
delivery could improve adherence for breast cancer patients.'
affiliation: 'Neuner, JM (Corresponding Author), Med Coll Wisconsin, Div Gen Internal
Med, Milwaukee, WI USA.
Neuner, Joan M., Med Coll Wisconsin, Div Gen Internal Med, Milwaukee, WI USA.
Neuner, Joan M.; Fergestrom, Nicole; Laud, Purushottam W., Med Coll Wisconsin, Ctr
Adv Populat Sci, Milwaukee, WI USA.
Pezzin, Liliana E., Med Coll Wisconsin, Inst Hlth \& Equity, Milwaukee, WI USA.
Laud, Purushottam W., Med Coll Wisconsin, Div Biostatist, Milwaukee, WI USA.
Ruddy, Kathryn J., Mayo Clin Rochester, Div Med Oncol, Rochester, MN USA.
Winn, Aaron N., Med Coll Wisconsin, Sch Pharm, Milwaukee, WI USA.'
author: Neuner, Joan M. and Fergestrom, Nicole and Pezzin, Liliana E. and Laud, Purushottam
W. and Ruddy, Kathryn J. and Winn, Aaron N.
author-email: jneuner@mcw.edu
author_list:
- family: Neuner
given: Joan M.
- family: Fergestrom
given: Nicole
- family: Pezzin
given: Liliana E.
- family: Laud
given: Purushottam W.
- family: Ruddy
given: Kathryn J.
- family: Winn
given: Aaron N.
da: '2023-09-28'
doi: 10.1007/s10549-022-06704-2
earlyaccessdate: NOV 2022
eissn: 1573-7217
files: []
issn: 0167-6806
journal: BREAST CANCER RESEARCH AND TREATMENT
keywords: Breast cancer; Medication adherence; Cost-related nonadherence
keywords-plus: 'HORMONAL-THERAPY; WOMEN; SYMPTOMS; SUPPORT; DISCONTINUATION;
NONADHERENCE; TAMOXIFEN; SURVIVORS; CARE'
language: English
month: JAN
number: '1'
number-of-cited-references: '42'
orcid-numbers: Neuner, Joan/0000-0003-0031-5988
pages: 223-233
papis_id: 7924be5e60cec03badb84c850ea1429f
ref: Neuner2023medicationdelivery
times-cited: '3'
title: Medication delivery factors and adjuvant endocrine therapy adherence in breast
cancer
type: article
unique-id: WOS:000882261500001
usage-count-last-180-days: '0'
usage-count-since-2013: '1'
volume: '197'
web-of-science-categories: Oncology
year: '2023'